Sat, Dec 27, 2014, 1:55 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

AVEO Pharmaceuticals, Inc. Message Board

  • taexpert928 taexpert928 May 23, 2013 8:04 PM Flag

    50% of biotech companies are trading below cash value. Cash burning is the reason

    Astellas does not intend to fund any future studies of tivozanib, in renal cell cancer. There are 2 options:

    1) AVEO continues alone a new P3 for RCC thus causing a huge cash burn

    2) AVEO terminates the TIVO study for RCC and as a result does not have anymore a potential important drug , Without any potential important drug , its market cap should be much less than $70M.

0.89+0.07(+8.54%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.